Table 2.

Summary estimate for unadjusted ORs of reduced estimated GFR according to anti-HCV serologic status

Study or SubcategoryAnti-HCV Positive (n/N)Anti-HCV Negative (n/N)OR (Random) (95% CI)Weight (%)OR (Random) (95% CI)
Tsui et al.(22)7/366630/14,663Embedded Image3.350.43 (0.20, 0.92)
Dalrymple et al.(23)93/19281423/23,85411.270.80 (0.64, 0.99)
Tsui et al.(24)10/52,87417/421,4953.164.69 (2.15, 10.24)
Tsui et al. (retrospective) (24)760/52,8744383/421,49513.791.39 (1.28, 1.50)
Moe et al.(25)248/3938745/920112.660.76 (0.66, 0.89)
Asrani et al.(27)682/13,3848172/154,18513.760.96 (0.89,1.04)
Asrani et al. (retrospective) (27)3677/806337,957/80,75914.100.95 (0.90, 0.99)
Lee et al.(26)1066/56836872/49,28313.861.42 (1.33, 1.53)
Butt et al.(28)3140/18,0023738/25,13714.051.21 (1.15, 1.27)
Total 157,1121,200,072100.001.07 (0.92, 1.25)
Total events968363,937
  • Test for heterogeneity: Chi square=201.96; df=8 (P<0.00001); I2=96.0%. Test for overall effect: Z=0.86 (P=0.39). OR, odds ratio; HCV, hepatitis C virus; NHANES, National Health and Nutrition Examination Survey; 95% CI, 95% confidence interval.